Request for Proposal (RFP)-Professional Medical Education:
BridgeBio Pharma, Inc. supports independent high-quality medical education programs which
provide fair-balanced, scientific information to healthcare professionals to improve patient care. Activities should be independent of commercial bias and be non-promotional in nature.
Key Dates:
- RFP Issues: March 18, 2025
- Applications due to BridgeBio: April 4th, 2025
- Notification of Grant Decisions: April 2025
- Educational Programming Starts: May/June 2025
Educational Topic: Implementation of Artificial Intelligence (AI) in Cardiovascular Care
Educational Need:
Artificial Intelligence (AI) is transforming cardiovascular care by improving diagnostics, risk
prediction, and clinical decision-making. AI is particularly impactful in echocardiography, where it enhances image interpretation, automates measurements, and facilitates disease detection.¹ AI is also demonstrating value in detecting and managing cardiovascular conditions such as atrial fibrillation (AF) and transthyretin amyloid cardiomyopathy (ATTR-CM), providing clinicians with powerful tools for early diagnosis and treatment planning.² As AI adoption grows, there is a critical need to educate healthcare providers on its capabilities, limitations, and ethical considerations. This needs assessment evaluates current gaps in knowledge and training to support the effective integration of AI in cardiovascular practice.